Eli Lilly and Company Posts Strong Q1 Results and Raises Full-Year Outlook

Eli Lilly and Company (NYSE: LLY) has entered 2026 with exceptional momentum, delivering a first quarter that reinforces its position as one of the most dominant growth stories in global pharmaceuticals.

Strong Start to 2026

The company reported first-quarter revenue of $19.8 billion, up 56% year over year. The growth was primarily volume-driven, with a 65% increase in demand across its portfolio, partially offset by a 13% decline in realized prices. Key Products revenue reached $13.4 billion, led by Mounjaro and Zepbound. Notably, the Immunology, Oncology, and Neuroscience therapeutic areas delivered a combined 160% increase, reinforcing Lilly’s diversification beyond diabetes and obesity treatments.

Geographically, performance was strong across the board. U.S. revenue rose 43% to $12.1 billion, supported by a 49% increase in volume, though partially offset by pricing pressure—particularly from Zepbound and Taltz. International markets outpaced domestic growth, with revenue surging 81% to $7.7 billion. This expansion was driven by a 95% increase in volume, especially for Mounjaro, although pricing declined 25% due to reimbursement dynamics, including its addition to China’s National Reimbursed Drug List. A one-time benefit of $250 million from Jardiance collaboration revenue also contributed to ex-U.S. performance, albeit lower than the prior year.

Earnings Surge on Expanding Operating Leverage

Despite pricing headwinds, Lilly maintained strong profitability. Gross margin increased 54% to $16.2 billion in Q1 2026, though margin as a percentage of revenue edged down slightly to 81.9%, reflecting pricing compression.

Operating leverage remained a key theme. Research and development expenses rose 28% to $3.5 billion (18% of revenue), underscoring continued investment in the company's early and late-stage portfolio. Meanwhile, marketing, selling, and administrative expenses increased 19% to $2.9 billion, driven by promotional activity tied to major product launches.

Importantly, acquired in-process research and development (IPR&D) charges declined sharply to $584 million, down 63% from $1.6 billion in the prior year, significantly reducing earnings drag. Additional charges of $279 million related primarily to litigation also impacted results.

The combination of strong top-line growth and disciplined cost scaling translated into a dramatic earnings expansion. Operating income surged 141% to $8.9 billion, with operating margin as a percentage of revenue expanding to 45% from 29% a year ago.

Net income reached $7.4 billion, up 168%, while EPS climbed 170% to $8.26 compared to $3.06 in Q1 2025. EPS in Q1 2026 and Q1 2025 included acquired IPR&D charges of $0.52 and $1.72, respectively.

Lilly also demonstrated a balanced capital allocation strategy, returning $3.9 billion to shareholders during the quarter. This included $1.5 billion in dividends and $2.4 billion in share repurchases.

Pipeline Progress and Strategic Acquisitions

Perhaps most significant for future valuation was the FDA approval of Foundayo (orforglipron)—the only approved GLP-1 pill that can be taken any time of day, without food and water restrictions. Foundayo will meaningfully expand the number of people who can benefit from GLP-1s.

Lilly’s pipeline remains highly active, with positive Phase 3 results across multiple therapeutic areas, including diabetes, oncology, and immunology—highlighting a diversified innovation engine. Concurrently, strategic acquisitions (Orna Therapeutics, Centessa Pharmaceuticals plc., Kelonia Therapeutics, and Ajax Therapeutics) signal continued external investment to sustain long-term growth beyond the current GLP-1 wave.

Raised Guidance Signals Confidence

Lilly now expects full-year 2026 revenue between $82 billion and $85 billion, up from the prior $80–$83 billion range. Non-GAAP EPS guidance was also lifted to $35.50–$37.00. Notably, performance margin guidance improved as well, indicating expectations for continued operating efficiency alongside top-line expansion.

Technical Outlook

From a technical perspective, the key resistance level sits at $1002 for LLY stock. A sustained breakout above this threshold would likely confirm bullish continuation, with the next upside target around $1081. This aligns with the strong fundamental backdrop and positive earnings momentum.

Conversely, failure to hold above $1002 could trigger a pullback phase. Initial support is identified at $867, which represents a near-term demand zone. If selling pressure intensifies, the stock may test a deeper support level at $793.